Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO 2022

ASCO 2022: Gut microbiome associated with increased immune cell infiltration in the tumour microenvironment and response to immunotherapy across cancer types

ASCO 2022: Gut microbiome associated with increased immune cell infiltration in the tumour microenvironment and...

ASCO 2022: Gut microbiome signatures associated with immunotherapy response in glioblastoma

ASCO 2022: Gut microbiome signatures associated with immunotherapy response in glioblastoma

ASCO 2022: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy

ASCO 2022: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid...

ASCO 2022: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

ASCO 2022: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

ASCO 2022: Combination regimen improves overall survival in a type of newly diagnosed metastatic colorectal cancer

ASCO 2022: Combination regimen improves overall survival in a type of newly diagnosed metastatic colorectal cancer

ASCO 2022: Autologous stem cell transplant showed improved progression-free survival in newly diagnosed multiple myeloma patients

ASCO 2022: Autologous stem cell transplant showed improved progression-free survival in newly diagnosed multiple...

ASCO 2022: Novel antibody-drug conjugate doubles progression-free survival in metastatic breast cancer with low HER2 expression levels

ASCO 2022: Novel antibody-drug conjugate doubles progression-free survival in metastatic breast cancer with low...

$ASCO 2022: High-dose ifosfamide demonstrated as a standard of care for recurrent and primary refractory ewing sarcoma$

ASCO 2022: High-dose ifosfamide demonstrated as a standard of care for recurrent and primary refractory ewing...

ASCO 2022: Lung cancer therapy could help patients live longer

ASCO 2022: Lung cancer therapy could help patients live longer

ASCO 2022: ASCO & WHO to collaborate on quality indicators for cancer facilities worldwide

ASCO 2022: ASCO & WHO to collaborate on quality indicators for cancer facilities worldwide

ASCO 2022: Immunotherapy before surgery associated with improved survival for soft-tissue sarcoma

ASCO 2022: Immunotherapy before surgery associated with improved survival for soft-tissue sarcoma

ASCO 2022: Drug combination shows promise against cancer’s ‘death star’ protein

ASCO 2022: Drug combination shows promise against cancer’s ‘death star’ protein

ASCO 2022: Novel agent increases PFS for patients with the most common type of advanced breast cancer

ASCO 2022: Novel agent increases PFS for patients with the most common type of advanced breast cancer

ASCO 2022: Liquid biopsy can help identify the need for adjuvant therapy in stage II colon cancer

ASCO 2022: Liquid biopsy can help identify the need for adjuvant therapy in stage II colon cancer

ASCO 2022: Ibrutinib improves progression-free survival by 50% for older patients with newly diagnosed mantle cell lymphoma

ASCO 2022: Ibrutinib improves progression-free survival by 50% for older patients with newly diagnosed mantle cell...

ASCO 2022: Nimotuzumab significantly improves overall survival for K-Ras wild-type advanced pancreatic cancer

ASCO 2022: Nimotuzumab significantly improves overall survival for K-Ras wild-type advanced pancreatic cancer

ASCO 2022: Follow-up data further support the superior efficacy of cabozantinib in patients with progressive differentiated thyroid cancer

ASCO 2022: Follow-up data further support the superior efficacy of cabozantinib in patients with progressive...

ECOG-ACRIN research highlights at ASCO 2022

ECOG-ACRIN research highlights at ASCO 2022

ASCO 2022: Acupuncture improves chronic radiation-induced dry mouth for patients with head and neck cancer

ASCO 2022: Acupuncture improves chronic radiation-induced dry mouth for patients with head and neck cancer

ASCO 2022: Targeting p53 pathway shows promise for patients with Merkel cell carcinoma

ASCO 2022: Targeting p53 pathway shows promise for patients with Merkel cell carcinoma

ASCO 2022: Novel immunotherapy combination improved survival in patients with metastatic melanoma

ASCO 2022: Novel immunotherapy combination improved survival in patients with metastatic melanoma

ASCO 2022: Patient-facing screening tool could increase detection of individuals with inherited cancer risk

ASCO 2022: Patient-facing screening tool could increase detection of individuals with inherited cancer risk

ASCO 2022: Study offers guidance for future trials of adjuvant therapy for patients with early HR+/HER2- breast cancer

ASCO 2022: Study offers guidance for future trials of adjuvant therapy for patients with early HR+/HER2- breast...

ASCO 2022: Endocrine sensitivity test predicts survival benefit of dose-dense chemotherapy for patients with HR+ breast cancer, study finds

ASCO 2022: Endocrine sensitivity test predicts survival benefit of dose-dense chemotherapy for patients with HR+...

ASCO 2022: Immunotherapy drug combination is safe with promising results in glioblastoma

ASCO 2022: Immunotherapy drug combination is safe with promising results in glioblastoma

ASCO 2022: Desmoplastic melanoma responds to PD-1 blockade immunotherapy

ASCO 2022: Desmoplastic melanoma responds to PD-1 blockade immunotherapy

ASCO 2022: Cell-free DNA methylation used to predict chemo benefit in bladder cancer

ASCO 2022: Cell-free DNA methylation used to predict chemo benefit in bladder cancer

More from ecancer